舒马曲普坦

舒马曲普坦
臨床資料
商品名（英语：Drug nomenclature）	Imitrex, Imigran ,Treximet
AHFS/Drugs.com	Monograph
核准狀況	美 FDA: Sumatriptan;
懷孕分級	C;
给药途径	tablet, subcutaneous injection, nasal spray
ATC碼	N02CC01 (WHO) ;
法律規範狀態
法律規範	美：处方药（℞-only）;
藥物動力學數據
生物利用度	15% (oral)/ 96% (s.c)
血漿蛋白結合率	14%-21%
药物代谢	MAO
生物半衰期	2.5 hours
排泄途徑	60% urine; 40% feces
识别信息
	IUPAC命名法 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]- N-methyl-methanesulfonamide; ;
CAS号	103628-46-2
PubChem CID	5358;
IUPHAR/BPS	54;
DrugBank	DB00669 ;
ChemSpider	5165 ;
UNII	8R78F6L9VO;
KEGG	D00451 ;
ChEBI	CHEBI:10650 ;
ChEMBL	ChEMBL128 ;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID4023628 ;
ECHA InfoCard	100.130.518
化学信息
化学式	C14H21N3O2S
摩尔质量	295.40 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES O=S(=O)(NC)Cc1cc2c(cc1)ncc2CCN(C)C;
	InChI InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3 ; Key:KQKPFRSPSRPDEB-UHFFFAOYSA-N ;

舒马曲普坦^[1]（INN：sumatriptan）又译舒马普坦、舒马曲坦 ，是一种曲普坦类药物（triptans）^[2]^[3]^[4]，为血清素 5-HT_1B/1D/1F 受体激动剂^[5]^[6]，用于缓解偏頭痛与丛集性头痛^[7]。曲普坦类选择性作用于颅内血管和三叉神经的感觉纤维，造成血管收缩和抑制三叉神经活性^[8]^[9]。

在结构上，舒马曲普坦和蟾毒色胺、5-甲氧基二甲基色胺一样是一种生物碱——二甲基色胺（DMT）的衍生物，其特点是二甲基N-乙酰基团连在吲哚环的5号位C上^[10]。

许多制药工厂都有生产舒马曲普坦，并以不同商品名出售，比如舒马普坦（Sumatriptan）、英明格（Imigran）、Imitrex、Treximet等等。

参考文献

^ 黄世杰.舒马曲普坦鼻粉剂用于治疗有或无预兆的偏头痛[J].国际药学研究杂志, 2016, 43(2):1.DOI:CNKI:SUN:GWYZ.0.2016-02-027.
^ 中国医师协会神经内科医师分会,中国研究型医院学会头痛与感觉障碍专业委员会,董钊,等.中国偏头痛诊治指南(2022版)[J].中国疼痛医学杂志, 2022, 28(12):881-898. [1]
^ Jerry W. Swanson; Manjit Matharu. Migraine Management. Elsevier. 2024: 24. ISBN 9780128234815.
^ Tepper SJ, Jenkins A, Henriksen C, Dai F, Atkinson J, Abraham L, Gendolla A. A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: A retrospective analysis of US claims data. Cephalalgia. 2025 Jul;45(7):3331024251352849. doi: 10.1177/03331024251352849. Epub 2025 Jul 27. PMID: 40717449.
^ Syed YY. Sumatriptan/Naproxen Sodium: A Review in Migraine. Drugs. January 2016, 76 (1): 111–121. PMID 26628293. S2CID 25060147. doi:10.1007/s40265-015-0521-8.
^ Rubio-Beltrán E, Labastida-Ramírez A, Villalón CM, MaassenVanDenBrink A. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?. Pharmacol Ther. June 2018, 186: 88–97. PMID 29352859. doi:10.1016/j.pharmthera.2018.01.005. hdl:1765/104159 .
^ Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. The Cochrane Database of Systematic Reviews. May 2014, 2014 (5): CD009108. PMC 6469574 . PMID 24865446. doi:10.1002/14651858.CD009108.pub2.
^ Gawel MJ. The new triptans. Can J Clin Pharmacol. 1999 Autumn;6 Suppl A:20A-4A. PMID: 10494008.
^ Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002 Jul;59(7):1084-8. doi: 10.1001/archneur.59.7.1084. PMID: 12117355.
^ The presence of the sulfonamide group in the molecule does not make sumatriptan a "sulfa drug", since it does not have any anti-microbial properties.

[1] 黄世杰.舒马曲普坦鼻粉剂用于治疗有或无预兆的偏头痛[J].国际药学研究杂志, 2016, 43(2):1.DOI:CNKI:SUN:GWYZ.0.2016-02-027.

[2] 中国医师协会神经内科医师分会,中国研究型医院学会头痛与感觉障碍专业委员会,董钊,等.中国偏头痛诊治指南(2022版)[J].中国疼痛医学杂志, 2022, 28(12):881-898. [1]

[3] Jerry W. Swanson; Manjit Matharu. Migraine Management. Elsevier. 2024: 24. ISBN 9780128234815.

[4] Tepper SJ, Jenkins A, Henriksen C, Dai F, Atkinson J, Abraham L, Gendolla A. A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: A retrospective analysis of US claims data. Cephalalgia. 2025 Jul;45(7):3331024251352849. doi: 10.1177/03331024251352849. Epub 2025 Jul 27. PMID: 40717449.

[5] Syed YY. Sumatriptan/Naproxen Sodium: A Review in Migraine. Drugs. January 2016, 76 (1): 111–121. PMID 26628293. S2CID 25060147. doi:10.1007/s40265-015-0521-8.

[6] Rubio-Beltrán E, Labastida-Ramírez A, Villalón CM, MaassenVanDenBrink A. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?. Pharmacol Ther. June 2018, 186: 88–97. PMID 29352859. doi:10.1016/j.pharmthera.2018.01.005. hdl:1765/104159 .

[Der2014-7] Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. The Cochrane Database of Systematic Reviews. May 2014, 2014 (5): CD009108. PMC 6469574 . PMID 24865446. doi:10.1002/14651858.CD009108.pub2.

[8] Gawel MJ. The new triptans. Can J Clin Pharmacol. 1999 Autumn;6 Suppl A:20A-4A. PMID: 10494008.

[9] Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002 Jul;59(7):1084-8. doi: 10.1001/archneur.59.7.1084. PMID: 12117355.

[10] The presence of the sulfonamide group in the molecule does not make sumatriptan a "sulfa drug", since it does not have any anti-microbial properties.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]